Merus N.V. (NASDAQ: MRUS) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab for head and neck cancer.
Merus N.V. (NASDAQ: MRUS) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab for head and neck cancer.
Copyright © Louis Velazquez. All Rights Reserved.